Pfizer's Hospital Business section acquires Arixa Pharma

▴ Pfizer's Hospital Business section acquires Arixa Pharma
Pfizer to develop ARX-1796 which, if approved, has potential to be the first novel oral beta-lactamase inhibitor + antibiotic combination in more than 35 years

Arixa’s lead compound, ARX-1796, is an oral prodrug of avibactam, a beta lactamase inhibitor (BLI) that was FDA-approved in 2015 as part of Avycaz (sold by Pfizer as Zaficefta outside the United States), an intravenous-only combination with ceftazidime for the treatment of a number of indications caused by Gram-negative pathogens. Arixa Co-Founder and CSO Dr Eric M. Gordon led a team to address the challenge of creating a viable prodrug of avibactam with now-patented chemistry. As a result of Arixa’s now patented chemistry, the prodrug of avibactam was 60-80% absorbed when administered orally to humans in a Phase 1 clinical trial, releasing the FDA-approved avibactam molecule in the bloodstream. In contrast, ~7% of the intravenous compound is absorbed orally. Combined with an antibiotic such as ceftibuten, Arixa’s ARX-1796, if approved, opens the way for orally-available avibactam to be part of a next-generation, oral antibiotic combination for resistant urinary tract and other infections.

“We are proud to have created and developed an important new drug candidate in a highly capital efficient manner, and believe Pfizer is the perfect company to take ARX-1796 into subsequent clinical trials and if approved, eventually to patients in need,” said John G. Freund MD MBA, Co-Founder and CEO, Arixa. “We built Arixa as a completely virtual company, with no employees and essentially no overhead - our work was performed by Contract Research Organizations under the supervision of a group of part-time expert consultants. This model has been behind the success of driving the developmental course of ARX-1796.”

“Through this acquisition, Pfizer will advance the development program for Arixa’s leading asset, ARX-1796. We are excited by the potential benefits ARX-1796 may provide to patients and the healthcare system overall, potentially allowing patients to leave the hospital earlier or avoid the need for hospital admission altogether,” said Annaliesa Anderson, Vice President and Chief Scientific Officer Bacterial Vaccines and Hospital, Pfizer.

“Beta-lactamase inhibitor combinations have become a mainstay of antimicrobial therapy, but clavulanic acid, approved by FDA in 1984, is the only inhibitor available to treat patients that is orally bioavailable,” said Karen Bush, Ph.D., an expert in beta-lactamase resistance and Professor of Practice, Biotechnology at Indiana University - Bloomington. Clavulanic acid is the BLI in Augmentin® (amoxicillin-clavulanic acid). “Avibactam has much broader coverage than clavulanic acid against beta lactamase enzymes that bacteria make to defend themselves against antibiotics such as penicillins, cephalosporins and carbapenems,” Dr Bush said.

“Common Gram-negative infections such as complicated urinary tract infections are becoming a major treatment challenge because of increasing rates of multidrug resistance,” said Jose Vazquez, M.D., Professor, Department of Medicine and Chief of Infectious Diseases at Medical College of Georgia at Augusta University. “There are a progressively larger number of patients who cannot be treated with oral antibiotics and we are forced to treat them with intravenous agents. The option to administer an oral antibiotic containing avibactam to my patients with infections due to pathogens resistant to other oral agents, and thus avoiding intravenous administration and a hospital stay, would always be considered an important advance.”

Tags : #Pfizer #LatestNewsonPfizer24thOct #ArixaPharma #LatestNewsonArixaPharma24thOct #LatestPharmaNews24thOct #LatestPharmaAcquisitionNews24thOct #DrEricMGordon #KarenBush #AnnaliesaAnderson #JoseVazquez

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Alembic Pharmaceuticals announces USFDA Final Approval for Metolazone TabletsDecember 03, 2020
QuEST Global provides COVID-19 support kits to more than 1,000 Police Officers in the cityDecember 03, 2020
Gujarat: Series of events mark ‘International Day of Persons with Disabilities’December 03, 2020
Number of COVID-19 positive cases rise in Mizoram, while COVID-19 recovery rate in Tripura improves December 03, 2020
IPC Statement On SARS-CoV-2 Vaccines And PsoriasisDecember 03, 2020
Roche receives USFDA emergency use authorization for new test to measure the level of SARS-CoV-2 antibodiesDecember 03, 2020
Country's COVID recovery rate reaches 94.11 per centDecember 03, 2020
Moderna CEO expects emergency use nod for COVID-19 vaccine after FDA panel meetDecember 03, 2020
Britain becomes first country in world to approve coronavirus vaccineDecember 03, 2020
Roche announces FDA approval of Gavreto for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancersDecember 03, 2020
Alembic Pharmaceuticals announces USFDA Final Approval for Metolazone Tablets USPDecember 03, 2020
Replacing red meat with plant foods may reduce the risk of heart diseaseDecember 03, 2020
Birth defects linked to greater risk of cancer in later lifeDecember 03, 2020
Combining telemedicine with AI will increase the productivity of clinicians and quality of care says Srinivas Prasad M R, Member, CII National Committee on Technology and R&DDecember 03, 2020
COVID is an opportunity to reshape the healthcare industry in India says Saurabh Bajpayee, Founder, Oxygenta HealthcareDecember 03, 2020
Second Covid wave expected to hit Karnataka in Jan-FebDecember 03, 2020
COVID19 cases: Maharashtra sees around 50% drop in November compared to October and SeptemberDecember 03, 2020
Moleculin announces FDA approval of 3 Rare pediatric disease designations for WP1066December 03, 2020
Health Decisions and OncoBay Clinical partners for development services in women's oncologyDecember 03, 2020
Impose Community service as penalty on those found violating COVID-19 safety norms: Gujarat High CourtDecember 03, 2020